Abstract
Background:
Gordon syndrome (GS) is a rare form of monogenic hypertension characterized by low renin hypertension, hyperkalemia, hyperchloremic metabolic acidosis, and normal glomerular filtration rate. To date, four genes causing GS have been identified as: WNK1, WNK4, CUL3, and KLHL3.
Case presentation:
We report three cases of GS in two families. All patients presented with typical clinical features of GS and had a known dominant KLHL3 mutation. Oral thiazide treatment with low salt diet resulted in normalization of blood pressure and serum electrolytes in all three cases.
Conclusions:
GS should be considered in patients with low renin hypertension and hyperkalemia. Although it is a rare disease, the correct diagnosis of GS is clinically important, as it can easily be treated with a low sodium diet or thiazides. In addition, family studies can identify individuals with undiagnosed GS as all mutations causing this disease, except for some recessive KLHL3 mutations, are dominant mutations.
Acknowledgments
This study was supported by a grant (HI12C0014) from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Gordon RD, Geddes RA, Pawsey CG, O’Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970;19:287–94.10.1111/imj.1970.19.4.287Search in Google Scholar PubMed
2. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964;2:305–6.10.5694/j.1326-5377.1964.tb115766.xSearch in Google Scholar PubMed
3. Gordon RD. The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon’s syndrome. Aust N Z J Med 1986;16:183–4.10.1111/j.1445-5994.1986.tb01145.xSearch in Google Scholar PubMed
4. Toka HR, Koshy JM, Hariri A. The molecular basis of blood pressure variation. Pediatr Nephrol 2013;28:387–99.10.1007/s00467-012-2206-9Search in Google Scholar PubMed
5. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, et al. Human hypertension caused by mutations in WNK kinases. Science 2001;293:1107–12.10.1126/science.1062844Search in Google Scholar PubMed
6. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012;482:98–102.10.1038/nature10814Search in Google Scholar PubMed PubMed Central
7. McCormick JA, Ellison DH. The WNKs: atypical protein kinases with pleiotropic actions. Physiol Rev 2011;91:177–219.10.1152/physrev.00017.2010Search in Google Scholar PubMed PubMed Central
8. Vitari AC, Deak M, Morrice NA, Alessi DR. The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J 2005;391(Pt 1):17–24.10.1042/BJ20051180Search in Google Scholar PubMed PubMed Central
9. Alessi DR, Zhang J, Khanna A, Hochdorfer T, Shang Y, et al. The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters. Sci Signal 2014;7:re3.10.1126/scisignal.2005365Search in Google Scholar PubMed
10. Yang SS, Fang YW, Tseng MH, Chu PY, Yu IS, et al. Phosphorylation regulates NCC stability and transporter activity in vivo. J Am Soc Nephrol 2013;24:1587–97.10.1681/ASN.2012070742Search in Google Scholar PubMed PubMed Central
11. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 2012;44:456–60, S1–3.10.1038/ng.2218Search in Google Scholar PubMed
12. Cope G, Murthy M, Golbang AP, Hamad A, Liu CH, et al. WNK1 affects surface expression of the ROMK potassium channel independent of WNK4. J Am Soc Nephrol 2006;17:1867–74.10.1681/ASN.2005111224Search in Google Scholar PubMed
13. Kahle KT, Wilson FH, Leng Q, Lalioti MD, O’Connell AD, et al. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet 2003;35:372–6.10.1038/ng1271Search in Google Scholar PubMed
14. Lazrak A, Liu Z, Huang CL. Antagonistic regulation of ROMK by long and kidney-specific WNK1 isoforms. Proc Natl Acad Sci USA 2006;103:1615–20.10.1073/pnas.0510609103Search in Google Scholar PubMed PubMed Central
15. Golbang AP, Murthy M, Hamad A, Liu CH, Cope G, et al. A new kindred with pseudohypoaldosteronism type II and a novel mutation (564D>H) in the acidic motif of the WNK4 gene. Hypertension 2005;46:295–300.10.1161/01.HYP.0000174326.96918.d6Search in Google Scholar PubMed
16. Glover M, Ware JS, Henry A, Wolley M, Walsh R, et al. Detection of mutations in KLHL3 and CUL3 in families with FHHt (familial hyperkalaemic hypertension or Gordon’s syndrome). Clin Sci (Lond) 2014;126:721–6.10.1042/CS20130326Search in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston
